Medical Research Council Unit The Gambia (MRCG)
Established in The Gambia in 1947, the MRCG is the UK's single largest investment in medical research in a developing country. The Unit's research focuses on infectious diseases of immediate concern to The Gambia, and the continent of Africa, with the aim of reducing the burden of illness and death in West Africa and the developing world as a whole. The MRCG led the clinical trials which led to the introduction of haemophilus and pneumococcal vaccines into the WHO-EPI program and continues to host landmark clinical trials of vaccines, including for maternal immunisation. The Vaccines & Immunity Theme, led by Prof Kampmann is one of 3 areas of investigative science in the MRCG and employs over 1200 people between the laboratory and field sites.
Within the PERISCOPE project the MRCG’s main tasks will be:
- Conduct of the maternal/infant immunisation trial in The Gambia (WP3)
- development of the clinical trial protocol
- submission of the clinical trial to Ethics
- liaison with regulatory authorities in the Gambia
- lead team for enrolment and follow up of trial subjects
- contribution to WP5 through development and conduct of novel cellular assays in the laboratories at the MRCG
Professor Beate Kampmann holds a Chair in Paediatric Infection & Immunity at Imperial College, London and is the Scientific Director for Vaccinology research at the MRCG. With over 15 years of extensive practical and research experience in childhood infection and immunity, she directs the Centre for International Child Health at Imperial College London and leads a comprehensive childhood infection and immunity research program both in the UK and sub-Saharan Africa.